Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) (ASPEN-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03608397

Recruitment Status : Completed

First Posted : August 1, 2018

Last Update Posted : December 5, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Syneos Health

Information provided by (Responsible Party):

Revance Therapeutics, Inc.

Results Submitted - Quality Control (QC) Review Has Not Concluded

Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status :	Completed
Actual Primary Completion Date :	December 3, 2019
Actual Study Completion Date :	June 16, 2020
Certification/Extension First Submitted :	December 22, 2020

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	April 13, 2023	May 5, 2023 Submission with QC Comments
2	May 30, 2023	May 31, 2023 Submission with QC Comments
3	June 21, 2023	June 22, 2023 Submission with QC Comments

To Top